ArQule's lead molecule moves into Phase III for lung cancer
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo and ArQule have recruited the first patient into an international Phase III clinical programme for ArQule's lead development project ARQ 197, for the treatment of locally advanced/metastatic non-small cell lung cancer (NSCLC).